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When people are dying and unable to take oral medication, injectable 
medication is commonly used, usually administered by healthcare 
professionals. There may be delays to symptom relief due to travel to the 
person’s home. In a randomised controlled trial (RCT) previously reported, 
nasal fentanyl (NF) or buccal midazolam (BM) were administered by lay 
carers in a hospice. 
 
Objective: (1) To report experiences of lay carers who administered NF and 
BM for symptom control (2) To use feedback to develop guidance informing a 
future definitive RCT to determine whether NF and BM administered by lay 
carers can lead to timely, improved symptom control for people dying at home 
and fewer ‘emergency’ community nursing visits than standard breakthrough 
medication administered by healthcare professionals. 
 
Material and methods: 
Semi-structured interviews with lay carers who gave trial medication were 
conducted. Interview data were analysed using a stage by stage method to 
code and categorise transcripts.   
 
Findings: 
The 6 themes were: 
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(1) Participation – lay carers welcomed the opportunity to administer 
medication. (2) Ease of use – lay carers found preparations easy to use. (3) 
How things could have been done differently – lay carers would have liked 
access to trial drugs at home. (4) Training – lay carers were happy with the 
training they received. (5) Timing – lay carers liked the immediacy of trial 
drugs. (6) Evaluation – assessing symptom intensity and drug efficacy. 
 
Conclusions: 
Participation was acceptable to patients and lay carers, and beneficial for 




People with terminal illnesses need access to symptom control and should be 
able to die in their ‘preferred place of care’1, for most at home2. Dying patients 
are often too weak to take medication orally and the mainstay of treatment in 
the United Kingdom (UK) is subcutaneous infusions by syringe pump and top-
up subcutaneous injections3. 
Family carers can be trained to give injections 4-6 and there has been 
increasing discussion of this practice to enable more people to remain and die 
at home during the COVID-19 pandemic7. 
There are preparations that offer an alternative and could be given more 
rapidly and easily than injections – fast acting fentanyl and BM. In preparation 
for a community based randomised trial of these modes of administration, it 
was important to assess feasibility. The findings from the open label feasibility 
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RCT are reported elsewhere8. Here, we report the nested qualitative 
component focused on the experiences of lay carers. 
Purpose of the study 
To explore the views and experiences of lay carers who administered NF or 
BM as breakthrough medication to their dying relative.  
Methodology 
The study was undertaken at a 16-bedded hospice in England. Lay carers 
were approached about participation. They were provided training related to 
medication administration (see Appendix 1) and a participant information 
leaflet. 
Lay carers were supported throughout the study by the research team and, 
once the patient died, we sought permission to contact them again three to six 
months later.  This timeframe allowed sensitivity around the death while being 
soon enough for recall. 
After this time, the lay carers were contacted and re-issued with a participant 
information leaflet. Following their consent to participate, arrangements were 
made to meet at a convenient place, to conduct the interview.  
Nine patients received NF or BM. Two had drugs administered only by 
nursing staff and not lay carers. Of the seven lay carers potentially eligible, 
the research and multidisciplinary team assessment was that one lay carer’s 
distress meant that they should not be approached.  
Six lay carers who administered breakthrough drugs were approached and 
four agreed; two did not respond.   
Written consent was obtained and interviews were semi-structured, digitally 
recorded and conducted by AP and BD using an interview guide (Appendix 2). 
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Interviews were digitally recorded and transcribed. The transcripts were 
checked by AP for accuracy. 
Following expert methodological advice from VT, an inductive analysis 
approach was used enabling patterns, themes and categories to emerge. 
Interview data were analysed using a stage by stage method9 comprising a 
systematic 14-stage approach to code and categorise semi-structured 
interview transcripts. Two researchers (AP and PP) generated themes 
independently to ensure accuracy of categorisation and reduce researcher 
bias. Themes generated were discussed and revised to clarify meanings of 
categories.  
Findings 








Time from patient 
death to interview 
(months) 
1 Daughter 55 4.5 
2 Wife 70 3.5 
3 Male partner 60 4 
4 Son and daughter 55 – 65 5 
Thematic analysis of transcripts identified 6 themes: 
(1) Participation (2) Ease of use (3) How things could have been done 








Each theme is discussed below, illustrated with quotes. 
1. Participation 
The main reason for participation was altruism.  
 
I think both of us felt that we could be of some use. You know give some help 
with research…it felt good, it felt like you were making – giving something 
back – sort of helping in research. It was great. You know yeah we were 
wearing our white coats. (P3) 
 
Lay carers also expressed the desire to help their loved one: 
 
It was a case of really trying to help Mum with the pain so we would have 
been willing to try anything. (P4) 
 
2. Ease of use 
 
Lay carers talked about preparations being easy to use and preferable to 
injections. However, most would have given injections if needed: 
 
Yeah I found it ok…She was happy with it and much preferred it over an 
injection… 
Interviewer: If you had been asked to participate in your Mum’s pain 
management by giving injections? 
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I would not have been so keen…Only because I knew she hated needles… 
But if I had had to do it – if it meant her in pain or not – I would of done it. No 
question but the very fact that it wasn’t an injection was the appeal really. (P1) 
 
3. How things could have been done differently 
 
All stated they wished that these drugs had been available at home for 
patients, earlier in illnesses. 
 
If they could have it earlier in the home…I think it would have been because I 
was at breaking point because of problems caused by the pain a lot of it. The 
fact that he was crying, I couldn’t stop it. (P2) 
 
There were concerns about administering preparations at home: 
 
I think it would feel different … I think it felt reassuring to be – to have the staff 
around – you could always check you had done it right or get some help or 
whatever so I suppose it would feel different if you were literally left on your 




Participants were all happy with training they received and felt prepared. 





Participants appreciated nurses being available to support them with drug 
administration. 
I had no problem when given very clear instructions, a couple of times run 
through it and then we were watched… the nurses would always be there…It 




Lay carers appreciated perceived immediacy of trial drugs and talked about 
having to wait for nurses’ visits when patients were at home. One respondent 
stated that they felt it could be a ‘stop-gap’ while waiting. 
 
My concern when she was at home was always [cries] – can I get hold of the 
district nurse to give her an injection or how long are they going to be? ‘cause 
I appreciate how busy they are. You know you may not coincide with a 
nurse’s visit so – I was a bit like my mum I didn’t want to bother people. You 
know – would I have gone out and given her an injection myself if it was that 
bad. I don’t know probably not. To have that ability to be able to give 
something without having to wait for a nurse to come – you know was 









I could tell from her expression on her face. (P1) 
 
They also reported evaluating how well medication had worked:  
 
Well through the whole time she was ill I think they gave us some indications, 
you know movement and stuff like that. I can’t quite remember what they were 
now. You kind of got used to picking up on that and I think I was quite happy 
about that because I know her so well. I just knew. P3 
 
Discussion 
Lay carers found buccal and nasal preparations easy to use, training and 
documentation to be adequate and had no recommendations about how 
these could be improved. They said that they would have used injections at 
home if needed.  
Our study is unique as it was conducted with lay carers giving medication 
while their relative was on an in-patient unit, meaning there was less 
emphasis on some issues from previous community studies. Participants 
mentioned that if they had been at home it would have felt like they had more 
responsibility; but did not raise concerns about needing particular 
organisational skills; or having 24/7 advice. It is likely this is because they had 
the constant support of the specialist palliative care unit’s staff to rely on. All 
talked about how they would have liked the opportunity to give trial medication 




Data from this research suggests that trial materials would be adequate for a 
future community study. Lay carers felt well supported by the hospice nursing 
team and were pleased to have nursing oversight when administering NF or 
BM for the first time. Well planned support for lay carers at home will need to 
be part of any future study including administration of first doses and 24/7 
access to advice. 
Limitations: 
We planned to recruit all lay carers who had given breakthrough medication in 
the experimental arms of the trial. We recruited a very ill, imminently dying 
population for the linked study, and not every patient received a dose of the 
trial medication administered by their lay carer before death; and not every lay 
carer who had given medication participated. Some were difficult to contact 
and it was inappropriate to make more than two attempts to contact them.  
 
Conclusions 
This embedded qualitative interview data yields helpful information for 
understanding the views and experiences of lay carers who administered 
buccal and nasal medication for breakthrough symptoms, previously 
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